Identifying unit costs for use in regional economic evaluation: An illustrative analysis of childhood pneumococcal conjugate vaccine in Latin America and the Caribbean

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 26, Issue 5, 2009, Pages 458-468

  Constenla, Dagna ^a   Sinha, Anushua ^b   Valencia, Juan Esteban ^c   Gomez, Elizabeth ^d   De La Hoz, Fernando ^e   Valenzuela, Maria Teresa ^f   De Quadros, Ciro A ^g  

^a Independent Department   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSIDAD CES   (Colombia)

^d Centro Nacional de Control de Enfermedades Tropicales   (Dominican Republic)

^e UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^f UNIVERSIDAD DE LOS ANDES   (Chile)

^g Albert B Sabin Vaccine Institute   (United States)

Author keywords

Caribbean Region; Cost of illness; Latin America; Methods; Streptococcus pneumoniae

Indexed keywords

BACTERIAL DISEASE; CHILD HEALTH; COST-BENEFIT ANALYSIS; REGIONAL ECONOMY; VACCINE;

CARIBBEAN COAST [COLOMBIA]; COLOMBIA; LATIN AMERICA;

STREPTOCOCCUS PNEUMONIAE;

EID: 73849123890     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892009001100011     Document Type: Article

References (12)

1. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care. 1990;6(1):57-75.
2. Sinha A, Constenla D, Valencia JE, O'Loughlin R, Gomez E, de la Hoz F, et al. Cost-effectiveness of pneumococcal conjugate vaccination in Latin America and the Caribbean: a regional analysis. Rev Panam Salud Publica. 2008;24(5): 304-313
3. Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, Knill-Kones RP, et al. Issues in the crossnational assessment of health technology. Int J Technol Assess Health Care. 1992;8(4):671-682
4. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
5. Hutton J, Politi C, Seeger T. Cost effectiveness of cochlear implantation of children: a preliminary model for the UK. Adv Otorhinolaryngol. 1995;50:201-206
6. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
7. Commonwealth Department of Health, Housing and Community Services (AU). Manual of resource items and their associated costs for use in submissions to the Pharmaceutical Benefits Advisory Committee involving economic analyses, August 1992. Canberra: Australian Government Publishing Service; 1992. p. 2-10.
8. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality [Internet]. HCUP NIS 2005 comparison report. Rockville (MD): DHHS, AHRQ; 2008 [updated 2008 May 5; cited 2009 Sep 10]. Available from: http://www.hcup-us.ahrq.gov/db/nation/nis/reports/2005niscomparisonrpt.jsp.
9. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187-195
10. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25(9):779-781
11. World Bank. World development indicators. Washington: The World Bank Group; 2005.
12. Constenla D. Evaluating the costs of pneumococcal disease in selected Latin American countries. Rev Panam Salud Publica. 2007;22(4):268-278